A Phase 3 interventional study of Relacorilant and Placebo in Hypercortisolism, sponsored by Corcept Therapeutics. Completed at 45 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Corcept Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cushing Syndrome by Corcept Therapeutics — none open to participants now, 1 under way, none of them phase 3. Cushing Syndrome · Corcept Therapeutics.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 12th registered.
123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.
Browse Cushing Syndrome studies →None of the 16 studies in Cushing Syndrome by Corcept Therapeutics is open now. The open studies under Cushing Syndrome, anywhere →
Of the 35 Cushing Syndrome studies recruiting now, 14 (40%) set no upper age limit and 10 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2020.
This study's enrollment of 137 is above the median of 44 across 58 interventional studies indexed under Cushing Syndrome.
Median enrollment 35 across the 11 interventional studies, 24 across the 5 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.
1 of the studies in Cushing Syndrome by Corcept Therapeutics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Cushing Syndrome by Corcept Therapeutics, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
The primary outcome measures of the study are 1) to assess the efficacy of relacorilant based on blood pressure control at Week 22 compared with placebo, and 2) to assess the safety of relacorilant based on adverse events. Patients will be randomized in a 1:1 ratio to treatment with relacorilant (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks. Patients who complete the study may also be eligible to roll over into an extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.
Drug: Relacorilant · Other: Placebo
Patients will receive placebo matched to study drug once daily.
Other: Placebo
Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
Also known as: CORT125134
Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
Change in Average 24-hour SBP
Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.
Time frame: Baseline and Week 22
Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.
Time frame: Baseline and up to Week 26
Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose)
AUCglucose was calculated based on results of the plasma 2-hour oGTT.
Time frame: Before and at time intervals up to 2 hours post glucose drink at Baseline and Week 22
Change in Average Diastolic Blood Pressure (DBP)
Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.
Time frame: Baseline and Week 22
Change in Average Heart Rate (HR)
Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.
Time frame: Baseline and Week 22
Change in Average Daytime and Nighttime SBP
Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.
Time frame: Baseline and Week 22
Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline
Time frame: Baseline and Week 22
Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline
Time frame: Baseline and Week 22
Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL
Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
Time frame: 2 hours post glucose drink at Week 22
Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL
Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
Time frame: 2 hours post glucose drink at Week 22
Number of Patients With Any Dose Decrease in Antihypertensive Medication
Time frame: Baseline and Week 22
Number of Patients With Any Dose Decrease in Diabetes Medication
Time frame: Baseline and Week 22
Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication
Time frame: Baseline and Week 22
Number of Patients With Any Dose Increase or Switch in Diabetes Medication
Time frame: Baseline and Week 22
Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5%
Time frame: Baseline and Week 22
Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg)
Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \<130 mm Hg at Week 22.
Time frame: Baseline and Week 22
Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg
Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.
Time frame: Baseline and Week 22
| Milestone | Relacorilant | Placebo |
|---|---|---|
| Started | 68 | 69 |
| Completed | 43 | 61 |
| Not completed | 25 | 8 |
| Withdrew: Adverse event | 12 | 2 |
| Withdrew: Withdrawal by subject | 10 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Subject does not want to continue with pi | 0 | 1 |
Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.
| mm Hg | Relacorilant | Placebo |
|---|---|---|
| Change in Average 24-hour SBP | -5.56 (-10.459 to -0.659) | -2.89 (-6.794 to 1.006) |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0. | 67 | 60 |
AUCglucose was calculated based on results of the plasma 2-hour oGTT.
| hours x mmol/L | Relacorilant | Placebo |
|---|---|---|
| Change in Area Under the Concentration-time Curve of Blood Glucose (AUCglucose) | -1.566 (-3.472 to 0.340) | 1.008 (-0.661 to 2.676) |
Blood pressure was measured by 24-hour ABPM. Daytime average DBP was measured from 06:00 to 21:59. Nighttime average DBP was measure from 22:00 to 05:59.
| mm Hg | Relacorilant | Placebo |
|---|---|---|
| 24-hour Average | -3.3 (-6.1 to -0.5) | -1.4 (-3.8 to 0.9) |
| Daytime Average | -3.1 (-6.0 to -0.1) | -1.0 (-3.5 to 1.6) |
| Nighttime Average | -3.0 (-6.4 to 0.5) | -0.6 (-3.5 to 2.4) |
Heart rate was measured by 24-hour ABPM. Daytime average HR was measured from 06:00 to 21:59. Nighttime average HR was measure from 22:00 to 05:59.
| Beats per minute | Relacorilant | Placebo |
|---|---|---|
| 24-hour Average | 2.0 (-0.4 to 4.5) | -2.0 (-4.1 to 0.1) |
| Daytime Average | 1.7 (-1.1 to 4.5) | -1.5 (-3.9 to 0.9) |
| Nighttime Average | 2.2 (-0.4 to 4.7) | -2.7 (-4.9 to -0.5) |
Blood pressure was measured by 24-hour ABPM. Daytime average SBP was measured from 06:00 to 21:59. Nighttime average SBP was measure from 22:00 to 05:59.
| mm Hg | Relacorilant | Placebo |
|---|---|---|
| Daytime Average | -4.5 (-9.0 to -0.1) | -2.5 (-6.3 to 1.4) |
| Nighttime Average | -4.6 (-9.9 to 0.6) | -3.0 (-7.5 to 1.4) |
| Percentage | Relacorilant | Placebo |
|---|---|---|
| Change in Hemoglobin HbA1c for Patients With HbA1c ≥5.7% at Baseline | -0.29 (-0.49 to -0.09) | 0.00 (-0.17 to 0.17) |
| Percentage | Relacorilant | Placebo |
|---|---|---|
| Change in HbA1c for Patients With HbA1c ≥6.5% at Baseline | -0.57 (-1.00 to -0.14) | -0.19 (-0.52 to 0.14) |
Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With DM Who Achieved 2-hour oGTT Glucose <140 mg/dL | 1 | 0 |
Glucose was measured using the 2 hour timepoint of the 2-hour oGTT.
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With IGT Who Achieved 2-hour oGTT Glucose <140 mg/dL | 6 | 7 |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With Any Dose Decrease in Antihypertensive Medication | 7 | 5 |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With Any Dose Decrease in Diabetes Medication | 0 | 0 |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With Any Dose Increase or Switch in Antihypertensive Medication | 1 | 5 |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With Any Dose Increase or Switch in Diabetes Medication | 4 | 3 |
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With HbA1c ≥6.5% at Baseline Who Achieved HbA1c <6.5% | 3 | 4 |
Blood pressure was measured by 24-hour ABPM Test. Reported is the number of patients with HTN at Baseline who achieved SBP \<130 mm Hg at Week 22.
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With Normalization of the 24-hour Average SBP (<130 mm Hg) | 9 | 13 |
Blood pressure was measured by 24-hour ABPM. Reported is the number of patients with HTN at Baseline who achieved at least a 5 mm Hg reduction in 24-hour average SBP at Week 22.
| Participants | Relacorilant | Placebo |
|---|---|---|
| Number of Patients With a Reduction in 24-hour Average SBP by ≥5 mm Hg | 10 | 13 |
Collected over Up to Week 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Relacorilant | 1/68 (1.5%) | 15/68 (22.1%) | 65/68 (95.6%) |
| Placebo | 0/69 (0%) | 4/69 (5.8%) | 60/69 (87%) |
| Event | Relacorilant | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/68 | 0/69 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/68 | 0/69 |
| Acral lentiginous melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/68 | 0/69 |
| Acute coronary syndromeCardiac disorders | 1/68 | 0/69 |
| Acute myocardial infarctionCardiac disorders | 1/68 | 1/69 |
| Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/68 | 0/69 |
| Coronary artery stenosisCardiac disorders | 1/68 | 0/69 |
| Foot fractureInjury, poisoning and procedural complications | 1/68 | 0/69 |
| Hepatic enzyme increasedInvestigations | 1/68 | 0/69 |
| Localised infectionInfections and infestations | 1/68 | 0/69 |
| Event | Relacorilant | Placebo |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 21/68 | 9/69 |
| FatigueGeneral disorders | 16/68 | 10/69 |
| Abdominal pain upperGastrointestinal disorders | 14/68 | 3/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/68 | 14/69 |
| NauseaGastrointestinal disorders | 13/68 | 8/69 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/68 | 5/69 |
| Abdominal painGastrointestinal disorders | 12/68 | 2/69 |
| HeadacheNervous system disorders | 7/68 | 12/69 |
| DizzinessNervous system disorders | 10/68 | 4/69 |
| DiarrhoeaGastrointestinal disorders | 9/68 | 6/69 |
The analysis population was patients in the Intent-to-treat (ITT) Population which included all randomized patients, even if they did not receive any study treatment.
| Age, Continuous(years) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Mean | 62.5 ± 9.11 | 63.0 ± 9.00 | 62.7 ± 9.02 |
| Sex: Female, Male(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Female | 50 | 49 | 99 |
| Male | 18 | 20 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 10 |
| Not Hispanic or Latino | 64 | 63 | 127 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 63 | 65 | 128 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Hypertension (HTN) only(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Count of participants | 20 | 21 | 41 |
| Diabetes mellitus (DM) or impaired glucose tolerance (IGT) only(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Count of participants | 26 | 27 | 53 |
| HTN and DM/IGT(Participants) | Relacorilant | Placebo | Total |
|---|---|---|---|
| Count of participants | 22 | 21 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Sep 2024, 49 months.
Results were first posted in Aug 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Relacorilant